Two breast cancer cell lines MCF7 (p53 wild-type, ER positive) and MDA-MB-231 (p53 mutant, triple negative) were selected based on their genetic backgrounds for investigating the in vitro activity of InuA and its molecular mechanisms. This evidence concerns the gene TP53 and breast cancer.